About atezolizumab
PD-L1 immune checkpoint inhibitor
Used for
- Certain cancers, including lung, liver, bladder, and breast cancers, depending on tumor type and treatment plan.
Usual adult dose
Usually 840 mg intravenously every 2 weeks, or 1,200 mg every 3 weeks, or 1,680 mg every 4 weeks. Some cancers use subcutaneous dosing every 3 weeks.
Common side effects
- Fatigue
- Nausea and reduced appetite
- Rash and itching
- Immune-related inflammation affecting organs such as lungs, bowel, liver, or thyroid
Important warnings
- Immune reactions can be serious or life-threatening and may begin during or after treatment.
- Report new breathing problems, severe diarrhea, yellowing skin, or unusual weakness promptly.
- Can cause infusion reactions; treatment requires specialist monitoring.
- May harm an unborn baby; effective contraception is advised during treatment and for five months afterward.
Pregnancy
May cause fetal harm; avoid during pregnancy. Use effective contraception during treatment and for five months after the last dose.
Breastfeeding
Breastfeeding is not recommended during treatment or for five months after the last dose.
Interactions
- No specific clinically important drug interactions are established; tell the cancer-care team about all medicines and supplements.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.